Biosimilar infliximab use in paediatric IBD

BACKGROUND: Biosimilar infliximab became available in the UK in 2015. Paediatric experience to date on its use is limited. We prospectively evaluated the safety and efficacy of biosimilar infliximab (Remsima) in two paediatric gastroenterology networks in patients with inflammatory bowel disease. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Richmond, Lisa, Curtis, Lee, Garrick, Victoria, Rogers, Pam, Wilson, Michelle, Tayler, Rachel, Henderson, Paul, Hansen, Richard, Wilson, David C, Russell, Richard K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Drug Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754881/
https://www.ncbi.nlm.nih.gov/pubmed/28988215
http://dx.doi.org/10.1136/archdischild-2017-313404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754881/
https://www.ncbi.nlm.nih.gov/pubmed/28988215
http://dx.doi.org/10.1136/archdischild-2017-313404

Ejemplares similares